Keith Vrbicky, MD
Obstetrics & Gynecology · Norfolk, NENPI 1477561660
Payments from drug & device makers
Across 1,535 payments — averaging $15,413 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$19.4M
- Pfizer$2.8M
- GSK$484K
- Seqirus USA Inc$436K
- Johnson & Johnson$129K
- Exeltis, USA Inc.$82K
- plus $347K from 23 others
What the payments were for
- Travel & lodging$16011%
- Food & beverage$1,21486%
- Gifts$332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 859 | $19,413,192 |
| Pfizer | 295 | $2,768,627 |
| GSK | 175 | $484,075 |
| Seqirus USA Inc | 22 | $435,596 |
| Johnson & Johnson | 4 | $128,533 |
| Exeltis, USA Inc. | 38 | $82,374 |
| Novavax Inc | 11 | $77,361 |
| Sanofi Pasteur Inc. | 12 | $75,874 |
| Sumitomo Pharma America, Inc. | 21 | $49,450 |
| Organon | 10 | $47,631 |
| Sanofi US Services Inc. | 10 | $31,605 |
| Biontech SE | 10 | $29,882 |
| Provepharm Inc. | 4 | $13,736 |
| Ferring International Pharmascience Center US | 7 | $9,125 |
| Janssen Research & Development, LLC | 5 | $6,585 |
| AbbVie(2 entities) | 23 | $4,929 |
| Daiichi Sankyo Inc. | 9 | $133 |
| Biohaven Pharmaceuticals, Inc. | 3 | $61 |
| Minerva Surgical, Inc | 1 | $56 |
| Novo Nordisk | 3 | $43 |
| Biogen | 2 | $39 |
| Astellas Pharma US Inc | 2 | $34 |
| Mayne Pharma Commercial LLC | 3 | $21 |
| Channel Medsystems, Inc. | 1 | $18 |
| AstraZeneca | 1 | $18 |
| Abbott | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Agile Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,659,056 in reported general payments places this provider in the 95th percentile of 242 obstetrics & gynecology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProgesteroneProgesterone, Micronized | 110 | $4,513 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 12 | $3,376 |
| Levothyroxine Sodium | 168 | $1,454 |
| Estradiol | 30 | $911 |
| Estradiol (Once Weekly)Estradiol | 15 | $872 |
| Risedronate Sodium | 12 | $611 |
| Liothyronine Sodium | 17 | $540 |
| Pravastatin Sodium | 12 | $532 |
| Oxybutynin Chloride ErOxybutynin Chloride | 24 | $461 |
| Rosuvastatin Calcium | 31 | $449 |
| Simvastatin | 42 | $431 |
| Losartan Potassium | 38 | $367 |
| Cyproheptadine Hcl | 20 | $331 |
| Omeprazole | 17 | $291 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 18 | $290 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKArexvy | $484,075 | $3,37612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 242 obstetrics & gynecology providers in Nebraska.
Other obstetrics & gynecology in Norfolk
- Keith VrbickyNorfolk$230K
- Tyler AdamHastings$2.8M
- Mark CarlsonElkhorn$474K
- John CoteOmaha$236K
- James MalyLincoln$197K
- Stephen SwansonLincoln$154K
- Gregory HeidrickLincoln$80K
- Jimmy KhandalavalaOmaha$32K
- Robin ClemmerOmaha$19K
- Angela GroneBeatrice$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.